| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gregory J Gores | Q91520926 |
| P2093 | author name string | Nataliya Razumilava | |
| P2860 | cites work | Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage | Q69825962 |
| Angiogenic awakening | Q74441666 | ||
| Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage | Q74605400 | ||
| Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis | Q77320788 | ||
| Preoperative biliary drainage for cancer of the head of the pancreas | Q82495675 | ||
| High lifetime risk of cancer in primary sclerosing cholangitis | Q82625908 | ||
| Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on | Q82637842 | ||
| Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents | Q83165167 | ||
| Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment | Q83234093 | ||
| Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings | Q83435113 | ||
| Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents | Q83998011 | ||
| Exome sequencing of liver fluke-associated cholangiocarcinoma | Q84073724 | ||
| Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma | Q84866519 | ||
| Stereotactic body radiotherapy for unresectable cholangiocarcinoma | Q84985390 | ||
| Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment | Q85115297 | ||
| Cancer genome landscapes | Q22242276 | ||
| Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas | Q24610836 | ||
| Opisthorchis viverrini: the carcinogenic human liver fluke | Q24658412 | ||
| Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies | Q27002547 | ||
| Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis | Q27026833 | ||
| Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation | Q27684364 | ||
| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 | ||
| Identification of targetable FGFR gene fusions in diverse cancers. | Q27852147 | ||
| Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours | Q28206040 | ||
| Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures | Q28253443 | ||
| IgG4-related disease | Q28259255 | ||
| Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update | Q28273143 | ||
| Classification, diagnosis, and management of cholangiocarcinoma | Q28275153 | ||
| Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome | Q28297967 | ||
| Efficacy and complications of covered Wallstents in malignant distal biliary obstruction | Q30436477 | ||
| Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study | Q33403174 | ||
| The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis | Q33886812 | ||
| Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy | Q33957032 | ||
| Hepatic and extrahepatic malignancies in primary sclerosing cholangitis | Q33957644 | ||
| Serum and bile markers for cholangiocarcinoma | Q33979059 | ||
| Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma | Q33979723 | ||
| Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study | Q33985725 | ||
| Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States | Q44002826 | ||
| Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? | Q44022677 | ||
| Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma | Q44096896 | ||
| Portal vein resection in management of hilar cholangiocarcinoma | Q44394476 | ||
| Relation of hepatolithiasis to helminthic infestation | Q44600744 | ||
| Constitutive Notch2 signaling induces hepatic tumors in mice | Q44601154 | ||
| Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma | Q44744688 | ||
| Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success | Q44866763 | ||
| Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma | Q45105343 | ||
| Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study | Q45394401 | ||
| Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection | Q45424625 | ||
| Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. | Q45809695 | ||
| Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma | Q46094093 | ||
| The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. | Q46160697 | ||
| The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. | Q46257880 | ||
| Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand | Q46547825 | ||
| Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis | Q48516720 | ||
| Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma | Q48568468 | ||
| Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial | Q49198674 | ||
| Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. | Q50149646 | ||
| Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. | Q51191058 | ||
| Intraductal tubular neoplasms of the bile ducts. | Q51302955 | ||
| Diagnosis and management of primary sclerosing cholangitis. | Q51726466 | ||
| Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. | Q53130915 | ||
| Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. | Q53241720 | ||
| Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. | Q53370566 | ||
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Q53393758 | ||
| Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. | Q55036188 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: A nationwide case-control study | Q58006620 | ||
| The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis | Q33989725 | ||
| Liver stem cells and their implication in hepatocellular and cholangiocarcinoma | Q33997118 | ||
| Outcomes after curative resections of cholangiocarcinoma | Q34061566 | ||
| Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea | Q34063702 | ||
| Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database | Q34077811 | ||
| Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | Q34104493 | ||
| Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. | Q34136980 | ||
| A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells | Q34212347 | ||
| miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma | Q34219872 | ||
| Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients | Q34337075 | ||
| Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. | Q34371376 | ||
| Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study | Q34506385 | ||
| Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution | Q34578979 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma | Q34626532 | ||
| Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. | Q34627825 | ||
| Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. | Q34627895 | ||
| Clinical diagnosis and staging of cholangiocarcinoma | Q34631337 | ||
| Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy | Q34635230 | ||
| Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination | Q34978340 | ||
| Risk factors for cholangiocarcinoma | Q35074664 | ||
| Cancer surveillance in patients with primary sclerosing cholangitis | Q35490961 | ||
| Intrahepatic cholangiocarcinoma: macroscopic type and stage classification | Q35575794 | ||
| A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction | Q35596459 | ||
| Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma | Q35659525 | ||
| Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping | Q35705307 | ||
| Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates | Q35798841 | ||
| The epidemiology of cholangiocarcinoma | Q35802314 | ||
| Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations | Q35831012 | ||
| Targeting the interleukin-6/Jak/stat pathway in human malignancies | Q35925127 | ||
| Bile duct cysts in adults | Q35953694 | ||
| Cholangiocarcinomas can originate from hepatocytes in mice | Q36129118 | ||
| Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma | Q36299709 | ||
| Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma | Q36545163 | ||
| Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk | Q36589096 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience | Q36644248 | ||
| Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma | Q36653219 | ||
| Hepatic resection in the treatment of hilar cholangiocarcinoma | Q36680831 | ||
| The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer | Q36683019 | ||
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes | Q36759538 | ||
| Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment | Q36900063 | ||
| Feasibility of the Glissonian approach during right hepatectomy | Q37064723 | ||
| Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China | Q37189634 | ||
| Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma | Q37246194 | ||
| microRNAs in liver disease: from diagnostics to therapeutics | Q37246198 | ||
| Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans | Q37286554 | ||
| Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma | Q37316693 | ||
| Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas | Q37401981 | ||
| Liver transplantation for cholangiocarcinoma | Q37760277 | ||
| Genetics of biliary tract cancers and emerging targeted therapies | Q37765099 | ||
| Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma | Q37918331 | ||
| The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma | Q37964960 | ||
| Endoscopic ultrasound staging of cholangiocarcinoma | Q37978485 | ||
| Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. | Q37994473 | ||
| Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. | Q37998654 | ||
| Toward personalized treatment of advanced biliary tract cancers | Q38030656 | ||
| Animal models of cholangiocarcinoma | Q38084044 | ||
| Endoscopic radiofrequency ablation for cholangiocarcinoma | Q38085459 | ||
| miRNA-Based Therapeutic Strategies | Q38092617 | ||
| Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. | Q39240982 | ||
| Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells | Q39450591 | ||
| The efficacy of portal vein embolization prior to right extended hemihepatectomy for hilar cholangiocellular carcinoma: a retrospective cohort study | Q39794366 | ||
| Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells | Q40172180 | ||
| Pathological classification of intrahepatic cholangiocarcinoma based on a new concept | Q41483428 | ||
| Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes | Q41626792 | ||
| Staging cholangiocarcinoma by imaging studies | Q41732674 | ||
| IDH1 and IDH2: not your typical oncogenes | Q42233066 | ||
| Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. | Q42457047 | ||
| Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. | Q43474554 | ||
| New staging system and a registry for perihilar cholangiocarcinoma | Q43564572 | ||
| Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification | Q43678782 | ||
| Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience | Q43873054 | ||
| Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study | Q43987886 | ||
| P433 | issue | 9935 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| P304 | page(s) | 2168-79 | |
| P577 | publication date | 2014-06-21 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Cholangiocarcinoma | |
| P478 | volume | 383 |
| Q37688222 | 14-3-3ζ and aPKC-ι synergistically facilitate epithelial-mesenchymal transition of cholangiocarcinoma via GSK-3β/Snail signaling pathway |
| Q35900738 | A Comprehensive Public Health Conceptual Framework and Strategy to Effectively Combat Cholangiocarcinoma in Thailand |
| Q88115617 | A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy |
| Q99581908 | A Patient's Journey With Rare Biphenotypic Hepatocellular Carcinoma and Cholangiocarcinoma |
| Q64057456 | A Simple Competing Endogenous RNA Network Identifies Novel mRNA, miRNA, and lncRNA Markers in Human Cholangiocarcinoma |
| Q37407304 | A case of distal extrahepatic cholangiocarcinoma with two positive resection margins |
| Q90462859 | A case report of rectal adenocarcinoma with intrahepatic cholangiocarcinoma of the liver |
| Q39160195 | A comparative proteomic analysis of bile for biomarkers of cholangiocarcinoma |
| Q36040441 | A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma. |
| Q92666355 | A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma |
| Q55068786 | A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma. |
| Q90601719 | A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance |
| Q89326683 | A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin |
| Q99580546 | A review of systemic therapy in biliary tract carcinoma |
| Q39330528 | Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma |
| Q47285445 | Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice |
| Q47161447 | Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4. |
| Q35728465 | Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III |
| Q35869828 | Adrenomedullin promotes intrahepatic cholangiocellular carcinoma metastasis and invasion by inducing epithelial-mesenchymal transition |
| Q54979818 | Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. |
| Q94571967 | Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection |
| Q26784091 | An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma |
| Q93159908 | Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway |
| Q89947281 | Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis |
| Q47132018 | Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma |
| Q92764838 | Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway |
| Q41670809 | Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. |
| Q52653077 | Application of 3D visualization and 3D printing technology on ERCP for patients with hilar cholangiocarcinoma. |
| Q94602757 | Application of photodynamic therapy for liver malignancies |
| Q57112122 | Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation |
| Q38962085 | Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection |
| Q47138859 | Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling |
| Q47134117 | Autoimmune Hepatitis: A Risk Factor for Cholangiocarcinoma |
| Q34121425 | Autophagy may promote carcinoma cell invasion and correlate with poor prognosis in cholangiocarcinoma |
| Q42560047 | Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma |
| Q57283068 | BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways |
| Q42199556 | Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells |
| Q64082772 | Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis |
| Q39396785 | Biliary cancer: Utility of next-generation sequencing for clinical management |
| Q92157282 | Biliary endoscopy in the management of primary sclerosing cholangitis and its complications |
| Q92431869 | Biliary stenting alone versus biliary stenting combined with 125I particles intracavitary irradiation for the treatment of advanced cholangiocarcinoma |
| Q90385469 | Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine |
| Q39279276 | Biliary tract cancer stem cells - translational options and challenges. |
| Q64102673 | Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology |
| Q26766699 | Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver |
| Q86015930 | Building a staircase to precision medicine for biliary tract cancer |
| Q47147339 | CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma |
| Q26865200 | Cancer review: Cholangiocarcinoma |
| Q35693567 | Cell-SELEX based selection and optimization of DNA aptamers for specific recognition of human cholangiocarcinoma QBC-939 cells. |
| Q35164379 | Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitro |
| Q46243039 | Characterisation of the immune-related transcriptome in resected biliary tract cancers |
| Q59793177 | Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence |
| Q46087686 | Cholangiocarcinoma - evolving concepts and therapeutic strategies |
| Q48121378 | Cholangiocarcinoma after choledochoduodenostomy |
| Q57150257 | Cholangiocarcinoma development: the resurgence of bile acids |
| Q60300564 | Cholangiocarcinoma: a guide for the nonspecialist |
| Q89996822 | Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy |
| Q89640274 | Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities |
| Q38597008 | Cholangiocarcinoma: from molecular biology to treatment |
| Q34959174 | Cholangiocarcinoma: molecular pathways and therapeutic opportunities |
| Q50047686 | Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression data. |
| Q57109524 | Cholangiopathies - Towards a molecular understanding |
| Q35829769 | Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies. |
| Q92273437 | Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma |
| Q90095646 | Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer |
| Q36245788 | Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma |
| Q38765797 | Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma |
| Q38701620 | Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. |
| Q37566921 | Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma |
| Q58804572 | Combined treatment of cholangiocarcinoma with interventional radiofrequency hyperthermia and heat shock protein promoter-mediated HSV-TK gene therapy |
| Q37131678 | Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma |
| Q90477659 | Comparison of the Clinical Outcomes of Suprapapillary and Transpapillary Stent Insertion in Unresectable Cholangiocarcinoma with Biliary Obstruction |
| Q88923207 | Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention |
| Q92340205 | Comprehensive analysis of DNA methylation and gene expression profiles in cholangiocarcinoma |
| Q92593276 | Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice |
| Q97419371 | Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience |
| Q104111257 | Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients |
| Q90705843 | Construction of a model to predict the prognosis of patients with cholangiocarcinoma using alternative splicing events |
| Q92096231 | Contrast-enhanced Ultrasound Features of Intrahepatic Cholangiocarcinoma: A New Perspective |
| Q40364663 | Control of Opisthorchis viverrini infection for cholangiocarcinoma prevention |
| Q32174351 | Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells |
| Q37742985 | Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma |
| Q38830071 | Current Progress in Immunotherapy for the Treatment of Biliary Cancers |
| Q39453572 | Current biologics for treatment of biliary tract cancers |
| Q90569988 | CyclinD1 inhibits dicer and crucial miRNA expression by chromatin modification to promote the progression of intrahepatic cholangiocarcinoma |
| Q47129097 | DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study |
| Q49317837 | DNA Methylation Markers Improve the Sensitivity of Endoscopic Retrograde Cholangiopancreatography-Based Brushing Cytology in Extrahepatic Cholangiocarcinoma |
| Q39349626 | Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. |
| Q50060693 | Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium. |
| Q93016751 | Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma |
| Q28073195 | Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers |
| Q52673450 | Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. |
| Q99558400 | Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers |
| Q53814608 | Diagnosis and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. |
| Q90324511 | Differences on metabolic behavior between intra and extrahepatic cholangiocarcinomas at 18F-FDG-PET/CT: prognostic implication of metabolic parameters and tumor markers |
| Q36922232 | Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. |
| Q38466472 | Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis |
| Q91737494 | Diosgenin Suppresses Cholangiocarcinoma Cells Via Inducing Cell Cycle Arrest And Mitochondria-Mediated Apoptosis |
| Q57114361 | Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma |
| Q39995898 | Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy |
| Q90494138 | Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study |
| Q37265309 | Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. |
| Q47135551 | Dynamic enhancement patterns of small-diameter mass-forming intrahepatic cholangiocarcinomas on contrast-enhanced magnetic resonance imaging: Challenges faced by the radiologist |
| Q64885161 | Dysregulated fatty acid metabolism in hepatocellular carcinoma. |
| Q89529851 | Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response |
| Q49952320 | Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. |
| Q64990052 | Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma. |
| Q49989661 | Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. |
| Q36171028 | Endoscopic radiofrequency ablation may be preferable in the management of malignant biliary obstruction: A systematic review and meta-analysis |
| Q30234461 | Epidemiology and risk factors: intrahepatic cholangiocarcinoma |
| Q47783721 | Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway |
| Q49663292 | Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives |
| Q92269441 | Establishment and Characterization of Two Novel Cholangiocarcinoma Cell Lines |
| Q89894899 | Expanding Indications for Liver Transplant: Tumor and Patient Factors |
| Q52649647 | Expression levels of serum miRNA-195 in different types of patients with cholangiocarcinoma and its value to determine the prognosis thereof. |
| Q64106126 | Expression of FOXP1 and FOXO3a in extrahepatic cholangiocarcinoma and the implications in clinicopathological significance and prognosis |
| Q36046443 | Expression of Molecular Differentiation Markers Does Not Correlate with Histological Differentiation Grade in Intrahepatic Cholangiocarcinoma |
| Q92604176 | Expression of endoplasmic reticulum oxidoreductase 1-α in cholangiocarcinoma tissues and its effects on the proliferation and migration of cholangiocarcinoma cells |
| Q52584337 | Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition. |
| Q35742526 | FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells |
| Q98945294 | Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma |
| Q50168153 | Fibroblast Growth Factor Receptor Inhibition induces loss of matrix MCL1 and necrosis in Cholangiocarcinoma. |
| Q26824969 | Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma |
| Q97074853 | Galangin Inhibits Cholangiocarcinoma Cell Growth and Metastasis through Downregulation of MicroRNA-21 Expression |
| Q55523920 | Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. |
| Q98159763 | Genetic analysis in the clinical management of biliary tract cancer |
| Q26852049 | Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies |
| Q91598439 | Genome-wide identification of a competing endogenous RNA network in cholangiocarcinoma |
| Q47248421 | Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma |
| Q53390123 | Genomic spectra of biliary tract cancer. |
| Q91966793 | Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through AKT Phosphorylation and Reactive Oxygen Species |
| Q41125809 | Guggulsterone-induced apoptosis in cholangiocarcinoma cells through ROS/JNK signaling pathway |
| Q57109153 | HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium |
| Q36041680 | HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma |
| Q37604222 | Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis |
| Q40625065 | Healthcare utilization and costs associated with cholangiocarcinoma |
| Q28076535 | Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma |
| Q92857226 | Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar Cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge |
| Q97681357 | High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer |
| Q92837764 | High expression of brain-derived neurotrophic factor in intrahepatic cholangiocarcinoma is associated with intraneural invasion and unfavorable prognosis |
| Q90273801 | High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection |
| Q49603070 | Hippo cascade controls lineage commitment of liver tumors in mice and humans |
| Q57824511 | Hyper- and hypothyroidism and gastrointestinal cancer risk: a Danish nationwide cohort study |
| Q37640879 | Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study |
| Q28828382 | Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes |
| Q90296922 | ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma |
| Q42594611 | IDH mutations in liver cell plasticity and biliary cancer |
| Q90706172 | Identification of candidate genes for the diagnosis and treatment of cholangiocarcinoma using a bioinformatics approach |
| Q92244861 | Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma |
| Q39179218 | Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis |
| Q38723527 | Imaging spectrum of cholangiocarcinoma: role in diagnosis, staging, and posttreatment evaluation |
| Q59358088 | Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis |
| Q60307070 | Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study |
| Q36611990 | Individualized preoperative planning using three-dimensional modeling for Bismuth and Corlette type III hilar cholangiocarcinoma |
| Q49166384 | Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system |
| Q58565330 | Inhibition of miR-10a-5p suppresses cholangiocarcinoma cell growth through downregulation of Akt pathway |
| Q57261202 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles |
| Q32173000 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles |
| Q90450411 | Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study |
| Q91606391 | Intrahepatic cholangiocarcinoma - influence of resection margin and tumor distance to the liver capsule on survival |
| Q39186928 | Intrahepatic cholangiocarcinoma: current management and emerging therapies |
| Q37669928 | Intrahepatic cholangiocarcinoma: current perspectives. |
| Q57820491 | Inverse Prognostic Relationships of F-FDG PET/CT Metabolic Parameters in Patients with Distal Bile Duct Cancer Undergoing Curative Surgery |
| Q36561746 | Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma |
| Q48365200 | Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases? |
| Q64053285 | Is exposure to tobacco associated with extrahepatic cholangiocarcinoma epidemics? A retrospective proportional mortality study in China |
| Q42342897 | Isocitrate Dehydrogenase Genes |
| Q33763540 | Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma |
| Q58728288 | Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1 |
| Q90657588 | Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma |
| Q47398665 | JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma |
| Q37525776 | Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans |
| Q97885864 | KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma |
| Q92421978 | LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma |
| Q90094624 | Latent Risk Intrahepatic Cholangiocarcinoma Susceptible to Adjuvant Treatment After Resection: A Clinical Deep Learning Approach |
| Q38613933 | Latest advances in the pathological understanding of cholangiocarcinomas |
| Q58547797 | Lentivirus-mediated overexpression of HSDL2 suppresses cell proliferation and induces apoptosis in cholangiocarcinoma |
| Q97644129 | Linc00473 potentiates cholangiocarcinoma progression by modulation of DDX5 expression via miR-506 regulation |
| Q91935265 | Linking Helicobacter pylori with gallbladder and biliary tract cancer in Moroccan population using clinical and pathological profiles |
| Q41581779 | Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker |
| Q35903794 | Liver cancer: Approaching a personalized care |
| Q46120476 | Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. |
| Q26783361 | Liver transplantation for cholangiocarcinoma: Current status and new insights |
| Q38248543 | Liver transplantation for intrahepatic cholangiocarcinoma |
| Q57149893 | Liver transplantation for intrahepatic cholangiocarcinoma |
| Q57149900 | Liver transplantation for intrahepatic cholangiocarcinoma--Authors' reply |
| Q49627939 | Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma |
| Q92618633 | LncRNA-SNHG3 is an independent prognostic biomarker of intrahepatic cholangiocarcinoma |
| Q55361097 | Long noncoding RNA LINC01296 promotes tumor growth and progression by sponging miR-5095 in human cholangiocarcinoma. |
| Q92182096 | Long noncoding-RNA component of mitochondrial RNA processing endoribonuclease is involved in the progression of cholangiocarcinoma by regulating microRNA-217 |
| Q36570284 | Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database |
| Q53201713 | Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin. |
| Q59137529 | M3 muscarinic acetylcholine receptors regulate epithelial-mesenchymal transition, perineural invasion, and migration/metastasis in cholangiocarcinoma through the AKT pathway |
| Q52966642 | MDCT assessment of resectability in hilar cholangiocarcinoma. |
| Q47429093 | MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma |
| Q38275161 | MRI of cholangiocarcinoma |
| Q90400285 | MSI2 knockdown represses extrahepatic cholangiocarcinoma growth and invasion by inhibiting epithelial-mesenchymal transition |
| Q38811107 | Management of patients with colorectal liver metastasis in eleven questions and answers |
| Q36884377 | Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients |
| Q47107479 | Mesenchymal stem cells in inflammatory microenvironment potently promote metastatic growth of cholangiocarcinoma via activating Akt/NF-κB signaling by paracrine CCL5. |
| Q64229475 | Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma |
| Q38710382 | Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells |
| Q37671148 | Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. |
| Q97423950 | Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma |
| Q52689433 | MiR-365 suppresses cholangiocarcinoma cell proliferation and induces apoptosis by targeting E2F2. |
| Q26865762 | MicroRNAs and benign biliary tract diseases |
| Q33991899 | MicroRNAs in Cholangiopathies |
| Q26783579 | MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment |
| Q90382152 | Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link |
| Q36488070 | Molecular genetics and targeted therapeutics in biliary tract carcinoma |
| Q38217475 | Molecular mechanism of cholangiocarcinoma carcinogenesis |
| Q35801459 | Multicentric recurrence of intraductal papillary neoplasms of bile duct in the remnant intrahepatic bile duct after curative resection |
| Q35842729 | Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer |
| Q94561340 | Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism |
| Q40051560 | Nanomedicines: a theranostic approach for hepatocellular carcinoma. |
| Q34365897 | Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target |
| Q98771112 | Negative Expression of DSG1 and DSG2, as Prognostic Biomarkers, Impacts on the Overall Survival in Patients with Extrahepatic Cholangiocarcinoma |
| Q89720598 | Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystec |
| Q90308323 | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma |
| Q89941822 | Nomograms predict survival outcome of Klatskin tumors patients |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q92602315 | Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma |
| Q35251736 | Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression |
| Q36501683 | Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice |
| Q92700859 | Optimizing the Method of Cell Separation from Bile of Patients with Cholangiocarcinoma for Flow Cytometry |
| Q50130190 | Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin. |
| Q52647722 | Overexpression of long non-coding RNA CRNDE facilitates epithelial-mesenchymal transition and correlates with poor prognosis in intrahepatic cholangiocarcinoma. |
| Q90291278 | Overexpression of miR-25 is associated with progression and poor prognosis of cholangiocarcinoma |
| Q91639115 | Overexpression of microRNA-96 is associated with poor prognosis and promotes proliferation, migration and invasion in cholangiocarcinoma cells via MTSS1 |
| Q40978367 | Overexpression of the X-linked ribosomal protein S4 predicts poor prognosis in patients with intrahepatic cholangiocarcinoma. |
| Q33648598 | PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. |
| Q52560186 | PGC1α promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect. |
| Q55210233 | Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma. |
| Q45870005 | Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. |
| Q90400187 | Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis |
| Q36520529 | Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma |
| Q37619847 | Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma. |
| Q26751416 | Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma - a systematic review and meta-analysis |
| Q37259964 | Performance of bile aspiration plus brushing to diagnose malignant biliary strictures during endoscopic retrograde cholangiopancreatography. |
| Q34673957 | Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications |
| Q35915338 | Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma |
| Q49178445 | Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient |
| Q98289747 | Platelet-derived PDGF promotes the invasion and metastasis of cholangiocarcinoma by upregulating MMP2/MMP9 expression and inducing EMT via the p38/MAPK signalling pathway |
| Q49267445 | Podoplanin is an important stromal prognostic marker in perihilar cholangiocarcinoma |
| Q38893743 | Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma. |
| Q94336862 | Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma |
| Q28079681 | Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update |
| Q91895949 | Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers |
| Q49874131 | Prediction of the histopathologic findings of intrahepatic cholangiocarcinoma: qualitative and quantitative assessment of diffusion-weighted imaging |
| Q92059497 | Preoperative gamma-glutamyltransferase to lymphocyte ratio predicts long-term outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection |
| Q55307435 | Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis. |
| Q93026711 | Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma |
| Q55076414 | Preoperative prediction of curative surgery of perihilar cholangiocarcinoma by combination of endoscopic ultrasound and computed tomography. |
| Q98386290 | Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma |
| Q47550861 | Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. |
| Q47563178 | Prognostic Impact of Cirrhosis in Patients with Intrahepatic Cholangiocarcinoma following Hepatic Resection. |
| Q36053164 | Prognostic Role of Mucin Antigen MUC4 for Cholangiocarcinoma: A Meta-Analysis |
| Q43170177 | Prognostic analysis of radical resection for intrahepatic cholangiocarcinoma: a retrospective cohort study |
| Q89538342 | Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma |
| Q92358689 | Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma |
| Q33829684 | Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis |
| Q98829675 | Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma |
| Q92684324 | Prognostic value of multiple epithelial mesenchymal transition-associated proteins in intrahepatic cholangiocarcinoma |
| Q91716424 | Prognostic value of site-specific metastases for patients with advanced intrahepatic cholangiocarcinoma: A SEER database analysis |
| Q89768129 | Prognostic values of a novel multi-mRNA signature for predicting relapse of cholangiocarcinoma |
| Q37321160 | Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. |
| Q37497846 | Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract. |
| Q55383888 | Pyrophosphatase 1 expression is associated with future recurrence and overall survival in Chinese patients with intrahepatic cholangiocarcinoma. |
| Q92651093 | Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma |
| Q35410253 | Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells |
| Q90198997 | RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding |
| Q33593244 | Radiation therapy for hepatobiliary malignancies |
| Q57118798 | Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) |
| Q57122007 | Rapidly Progressing Primary Extrahepatic Bile Duct Signet-Ring Cell Carcinoma in a Caucasian Woman |
| Q37606680 | Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma. |
| Q28075361 | Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI |
| Q91737464 | Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway |
| Q35956552 | Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor δ (PPARδ) in human cholangiocarcinoma |
| Q40703610 | Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models |
| Q37534719 | Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients |
| Q36409556 | Retinal and vitreous metastases from hepatocholangiocarcinoma |
| Q33869560 | Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection. |
| Q92875468 | Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications |
| Q92135841 | Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma |
| Q58758006 | Role of canonical Hedgehog signaling pathway in liver |
| Q38779843 | Role of circulating microRNAs in liver diseases |
| Q38362946 | Role of hepatocyte nuclear factor 4α (HNF4α) in cell proliferation and cancer |
| Q57110767 | SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma |
| Q93146712 | SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis |
| Q91716682 | Safety and feasibility of laparoscopic liver resection for patients with large or multiple intrahepatic cholangiocarcinomas: A propensity score based case-matched analysis from a single institute |
| Q49933007 | Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery |
| Q36411789 | Sarcopenia as a prognostic factor in hepatolithiasis-associated intrahepatic cholangiocarcinoma patients following hepatectomy: a retrospective study |
| Q36000994 | Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? |
| Q64075300 | Second primary malignancy in patients with cholangiocarcinoma: a population-based study |
| Q28550991 | Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures |
| Q40104458 | Serum N-glycans outperform CA19-9 in diagnosis of extrahepatic cholangiocarcinoma. |
| Q48553032 | Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. |
| Q61447152 | Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma |
| Q57457475 | Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis |
| Q55230662 | Solamargine derived from Solanum nigrum induces apoptosis of human cholangiocarcinoma QBC939 cells. |
| Q89824421 | Somatic mutation landscape reveals differential variability of cell-of-origin for primary liver cancer |
| Q60922109 | Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection |
| Q61455701 | Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report |
| Q34778995 | Suppression of Ov-grn-1 encoding granulin of Opisthorchis viverrini inhibits proliferation of biliary epithelial cells |
| Q41345470 | Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma |
| Q40044470 | Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. |
| Q41677917 | Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified? |
| Q50526996 | Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. |
| Q53263862 | Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. |
| Q57073990 | Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma |
| Q57115352 | Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer |
| Q92917094 | TGR5 promotes cholangiocarcinoma by interacting with mortalin |
| Q30234532 | Targeted therapy in biliary tract cancers-current limitations and potentials in the future |
| Q64113657 | Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma |
| Q64072869 | Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma |
| Q59793915 | Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling |
| Q27340125 | The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells |
| Q64099576 | The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics |
| Q60922992 | The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis |
| Q92996083 | The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway |
| Q49907714 | The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma |
| Q35814659 | The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma |
| Q50350640 | The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. |
| Q64104356 | The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming |
| Q57113431 | The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis |
| Q93160236 | The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer |
| Q33740551 | The real-time dynamic monitoring of microRNA function in cholangiocarcinoma |
| Q38271374 | The role of polycomb repressive complexes in biliary tract cancer. |
| Q90113516 | Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma |
| Q90012705 | Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma |
| Q99352179 | Therapy of Primary Liver Cancer |
| Q45325268 | Transarterial Chemoembolization: A Favorable Postoperative Management to Improve Prognosis of Hepatitis B Virus-associated Intrahepatic Cholangiocarcinoma after Surgical Resection |
| Q93086061 | Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1 |
| Q90216463 | Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma |
| Q40778548 | Treatment of Leptomeningeal Carcinomatosis in a Patient With Metastatic Cholangiocarcinoma |
| Q92350797 | Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy |
| Q42371988 | Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. |
| Q64113017 | Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma |
| Q99720308 | Tumor-derived microparticles in tumor immunology and immunotherapy |
| Q37269146 | Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations |
| Q93103786 | Type 3 Inositol 1,4,5-Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma |
| Q43113709 | Unusual presentation of a distal cholangiocarcinoma |
| Q38940940 | Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications |
| Q30238895 | Update on the Diagnosis and Treatment of Cholangiocarcinoma |
| Q49923383 | Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer. |
| Q91142660 | Upregulated expression of HOXB7 in intrahepatic cholangiocarcinoma is associated with tumor cell metastasis and poor prognosis |
| Q47299042 | Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma |
| Q64935824 | Upregulation of gastric adenocarcinoma predictive long intergenic non-coding RNA promotes progression and predicts poor prognosis in perihilar cholangiocarcinoma. |
| Q90571093 | Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer |
| Q91656872 | Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y está justificada? |
| Q38786803 | WAVE3 Induces EMT and Promotes Migration and Invasion in Intrahepatic Cholangiocarcinoma |
| Q92610705 | Weighted gene coexpression network analysis reveals hub genes involved in cholangiocarcinoma progression and prognosis |
| Q91587954 | Wnt/β-Catenin Signaling in Liver Cancers |
| Q50577910 | YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. |
| Q58102813 | Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience |
| Q38739690 | Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma |
| Q28083856 | Yttrium-90 microspheres: a review of its emerging clinical indications |
| Q37151082 | Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study |
| Q58562671 | [Frontiers in liver transplantation in indication and techniques] |
| Q50962965 | aPKC-ι/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma. |
| Q91785168 | lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma |
| Q64117214 | lncRNAs as potential molecular biomarkers in the clinicopathology and prognosis of cholangiocarcinoma: a systematic review and meta-analysis |
| Q38721397 | miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation |
| Q92276464 | miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5 |
| Q89702881 | β-Eudesmol induces the expression of apoptosis pathway proteins in cholangiocarcinoma cell lines |
Search more.